Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab in secondary angiosarcoma
NL-OMON55079Phase 2Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in angiosarcoma and soft tissue sarcoma (STS), sponsored by Radboud University Medical Center. Primary endpoint: Overall response rate at 24 weeks. Started Mar 2022; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
angiosarcomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NL-OMON55079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55079.